Compare TLYS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | VERU |
|---|---|---|
| Founded | 1982 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 40.9M |
| IPO Year | 2011 | 1996 |
| Metric | TLYS | VERU |
|---|---|---|
| Price | $4.23 | $2.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 228.6K | 54.9K |
| Earning Date | 06-03-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | $4.66 | N/A |
| Revenue Next Year | $1.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.36 |
| 52 Week High | $5.54 | $4.59 |
| Indicator | TLYS | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 46.04 |
| Support Level | $3.62 | $2.12 |
| Resistance Level | $4.59 | $2.67 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 56.68 | 50.00 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.